Male Infertility Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Male infertility is defined as the failure to achieve pregnancy after 12 months of regular, unprotected intercourse with a fertile female partner. It is implicated in approximately 50% of all infertile couples, either as the sole cause or as a contributing factor. Approximately 7% of all men are affected.

Evaluation begins with a detailed reproductive and medical history, physical examination (testicular volume by Prader orchidometer, presence of vas deferens, epididymal fullness, varicocele assessment on Valsalva), and two semen analyses separated by at least 4 weeks. The most recent WHO 2021 (6th edition) lower reference limits are:

• Sperm concentration: ≥16 million/mL
• Total sperm number per ejaculate: ≥39 million
• Progressive motility (PR): ≥30%
• Total motility (PR + NP): ≥42%
• Morphology (Kruger strict criteria): ≥4% normal forms
• Semen volume: ≥1.4 mL

Hormonal evaluation includes serum FSH, LH, total and free testosterone, prolactin, and thyroid function tests. Serum inhibin B, produced by Sertoli cells, is a sensitive marker of spermatogenesis: a level ≥80 pg/mL with normal FSH strongly suggests obstructive azoospermia (OA), whereas undetectable inhibin B combined with elevated FSH indicates non-obstructive azoospermia (NOA) with testicular failure.

Male infertility encompasses a spectrum of aetiologies, each requiring a targeted therapeutic strategy:

• Varicocele (WHO Grade I–III): Abnormal dilation of the pampiniform venous plexus causing retrograde venous reflux, increased scrotal temperature, oxidative stress, and impaired spermatogenesis. Grade I is palpable only on Valsalva; Grade II is palpable without Valsalva; Grade III is visually apparent. Present in 35–40% of infertile men and 15% of the general population. Cochrane meta-analysis (Kroese et al.) and SART-linked data confirm that Grade II–III repair in men with abnormal semen parameters significantly improves pregnancy outcomes.
• Obstructive Azoospermia (OA): Sperm production is normal but egress is blocked. Causes include post-vasectomy obstruction, epididymal obstruction (post-infective, e.g., chlamydia or gonorrhoea), ejaculatory duct obstruction (cyst or calculus), and congenital bilateral absence of the vas deferens (CBAVD).
• Congenital Bilateral Absence of the Vas Deferens (CBAVD): Associated with CFTR gene mutations (the same gene responsible for cystic fibrosis); identified in ~1–2% of infertile men. Partner must be CFTR carrier-screened before any treatment to assess risk of offspring with cystic fibrosis.
• Non-Obstructive Azoospermia (NOA): Impaired or absent spermatogenesis. Causes include Klinefelter syndrome (47,XXY — the most common genetic cause), Y-chromosome AZF microdeletions, maturation arrest, Sertoli-cell-only syndrome, cryptorchidism, chemotherapy/radiotherapy, and idiopathic causes.
• Retrograde Ejaculation: Semen is propelled retrograde into the bladder due to failure of bladder neck closure during orgasm. Confirmed by finding >10–15 sperm/HPF in post-ejaculatory urine. Causes include diabetes mellitus neuropathy, retroperitoneal lymph node dissection, transurethral prostate surgery, alpha-blocker medications, and spinal cord injury.
• Hypogonadotrophic Hypogonadism (HH): Low LH and FSH from hypothalamic (Kallmann syndrome — anosmia + GnRH deficiency) or pituitary disease (adenoma, haemochromatosis) causing secondary testicular failure.
• Hyperprolactinaemia: Elevated prolactin (from prolactinoma or medications) suppresses GnRH pulsatility, reducing LH/FSH and testosterone with resultant oligospermia or azoospermia.

Candidacy is determined after a complete andrological and couple fertility evaluation:

• Microsurgical varicocelectomy: Men with a palpable (clinical) Grade II–III varicocele, at least one abnormal semen parameter on two analyses, and a female partner with normal or correctable fertility. Sub-clinical varicoceles detected only on Doppler ultrasound are not routinely treated per EAU (2023) and AUA guidelines.
• Surgical sperm retrieval (PESA/TESA/microTESE): Men with confirmed azoospermia (OA or NOA) who either decline or are not candidates for reconstructive surgery. For NOA, mandatory pre-operative genetic testing: karyotype and AZF microdeletion analysis. Complete AZFa or AZFb deletions predict zero sperm retrieval and preclude microTESE.
• Surgical reconstruction: Men with post-vasectomy or acquired OA who want natural conception. Microsurgical vasovasostomy success rates are >90% if <3 years post-vasectomy, declining to ~30% at >15 years. Vasoepididymostomy is required if epididymal obstruction is identified intraoperatively.
• Hormonal stimulation (hCG + FSH): Men with hypogonadotrophic hypogonadism. Critically, testosterone replacement therapy must be stopped at least 3–6 months before fertility treatment, as exogenous testosterone profoundly suppresses FSH and LH (and thus spermatogenesis) via negative pituitary feedback.
• Cabergoline: Men with confirmed hyperprolactinaemia (prolactin >400 mIU/L) causing impaired sperm production, after ruling out hypothyroidism and medication-induced causes.
• Genetic counselling: Recommended for all men with severe oligospermia (<5 million/mL), azoospermia, Klinefelter syndrome, CBAVD, AZF deletions, or a positive family history of chromosomal disorders.

1. Microsurgical Varicocelectomy
The subinguinal microsurgical approach (Marmar technique) is the gold standard, providing the lowest recurrence (<1–2%) and post-operative hydrocele rates (<1–2%) compared to the open high ligation (Palomo) approach (hydrocele 5–10%) or laparoscopic repair. The spermatic artery and lymphatics are carefully preserved under 6–25x magnification. Mean time to maximal semen improvement is 6 months; pregnancy rates of 36–43% at 1 year in well-selected couples.

2. Surgical Sperm Retrieval

• PESA (Percutaneous Epididymal Sperm Aspiration): Fine-needle aspiration of the epididymis under local or sedation anaesthesia. Used primarily in OA (particularly CBAVD). High sperm yield suitable for ICSI; fresh or cryopreserved sperm used. Risk of epididymal scarring may compromise future reconstruction.
• TESA (Testicular Sperm Aspiration): Percutaneous needle biopsy of the testis. Used in OA when PESA fails or vas is absent. Lower sperm yield than PESA; suitable for ICSI.
• microTESE (Microsurgical Testicular Sperm Extraction): Pioneered by Schlegel (Cornell University, 1999). A wide equatorial incision is made in the tunica albuginea under an operating microscope; dilated, opaque seminiferous tubules (indicating active spermatogenesis) are selectively excised from the background of smaller, translucent, non-productive tubules. Sperm retrieval rate of 40–60% in NOA, significantly superior to conventional TESE (~30%). Retrieved sperm are cryopreserved for subsequent ICSI cycles. Concurrent testicular androgen optimisation (hCG pre-treatment for 3–4 months) may improve retrieval rates in selected patients with low testosterone.

3. Hormonal and Medical Therapy

• Hypogonadotrophic hypogonadism: First-line treatment is hCG 1,500–2,000 IU IM/SC 2–3 times per week to stimulate intratesticular testosterone (a prerequisite for spermatogenesis). After 6 months, if azoospermia persists, add recombinant FSH 75–150 IU SC 3 times per week. Overall pregnancy rates are 50–90% depending on the severity of gonadotrophin deficiency and prior treatment history. Pulsatile GnRH via pump therapy is available at specialist centres.
• Hyperprolactinaemia: Dopamine agonist cabergoline 0.25–0.5 mg twice weekly orally normalises serum prolactin within 4–8 weeks, restoring GnRH pulsatility and FSH/LH secretion. Semen parameters typically improve within 3–6 months. Bromocriptine is an older alternative with more side effects.
• Retrograde ejaculation: Alpha-adrenergic sympathomimetic agents (pseudoephedrine 60 mg four times daily or imipramine 25 mg twice daily) restore bladder neck closure during ejaculation in neurologically intact men. Contraindicated in hypertension. When pharmacotherapy fails: urinary sperm retrieval — alkalinise urine to pH 7.2–8.4 pre-ejaculation with oral sodium bicarbonate 3 g, void, ejaculate, then catheterise and centrifuge urine specimen to retrieve motile sperm for IUI or IVF/ICSI.

4. Reconstructive Surgery

• Vasovasostomy: Microsurgical multi-layer (modified one-layer or two-layer) anastomosis of the vas deferens for vasectomy reversal. Patency rates: >90% if <3 years post-vasectomy; ~70% at 3–8 years; ~30–50% at 9–14 years; ~30% at ≥15 years.
• Vasoepididymostomy: Intussusception microsurgical anastomosis of the vas to the epididymal tubule, required when epididymal obstruction or blowout is found intraoperatively. Technically demanding; 40–60% patency at experienced centres.
• Transurethral Resection of Ejaculatory Ducts (TURED): Endoscopic resection for ejaculatory duct obstruction from midline cysts or calculi, accessing via the verumontanum. Success (sperm in ejaculate) in approximately 50–70% of cases.

• Natural conception: Varicocele repair and reconstructive microsurgery enable natural or IUI-assisted pregnancy without IVF/ICSI in appropriately selected couples, with fewer ethical, physical, and financial burdens.
• Improved semen parameters: Microsurgical varicocelectomy improves total motile sperm count in 66–70% of treated men and pregnancy rates by approximately 36–43% at one year (EAU Guidelines 2023, Cochrane 2012).
• Cost-effectiveness over IVF: Decision-analysis models consistently show that correcting correctable male factor causes (varicocele, ejaculatory duct obstruction) before proceeding to IVF/ICSI is significantly more cost-effective per live birth.
• Biological parenthood in azoospermia: microTESE with ICSI achieves clinical pregnancy rates of 25–50% per embryo transfer cycle in NOA, enabling biological fatherhood where none was previously possible.
• Hormonal and systemic benefits: Treating hypogonadism and hyperprolactinaemia restores testosterone, improving libido, energy, bone mineral density, mood, and cardiovascular metabolic profiles — benefits extending well beyond fertility.
• Informed reproductive planning: Genetic counselling for Klinefelter syndrome, AZF deletions, or CFTR mutations enables couples to make fully informed decisions about natural conception risks, preimplantation genetic testing (PGT), donor gametes, or adoption.

• Microsurgical varicocelectomy: Hydrocele formation (<2% with microscopic subinguinal approach), testicular artery injury (<1% at experienced centres, rarely causing testicular atrophy), varicocele recurrence (1–2%), haematoma, wound infection.
• microTESE: Failure to retrieve sperm (~40–60% probability of failure in NOA); peri-operative haematoma; testicular atrophy (rare but irreversible with aggressive bilateral dissection); pain. The procedure does not permanently reduce testosterone levels when performed carefully.
• PESA/TESA: Epididymal fibrosis (which may preclude future microsurgical reconstruction), haematoma, infection, pain; sperm quality may be lower than surgically retrieved testicular sperm.
• Vasectomy reversal: Anastomotic failure (especially if long interval), need for conversion to vasoepididymostomy, haematoma (2–3%), infection, persistent azoospermia.
• Hormonal therapy (hCG + FSH): Gynaecomastia, polycythaemia, fluid retention, acne. Theoretical concern of stimulating occult Leydig cell tumour. Long-term treatment required — often 18–24 months.
• Cabergoline: Nausea, headache, postural hypotension. Cardiac valve fibrosis is associated with high-dose dopamine agonist therapy (as used in Parkinson's disease) — the much lower doses used for hyperprolactinaemia carry negligible valve risk.
• Genetic inheritance risks: AZFc microdeletion is transmitted to all male offspring via ICSI; couples should be counselled about PGT for sex selection if desired. CBAVD offspring risk of cystic fibrosis depends on partner's CFTR status.

Ongoing monitoring is integral to optimising outcomes:

• After varicocelectomy: Repeat semen analysis at 3 and 6 months post-operatively. Also reassess serum testosterone (varicocelectomy improves testosterone in ~14% of hypogonadal men with varicocele). If no significant improvement by 6 months, escalate to IVF/ICSI with the available sperm.
• After microTESE: Testicular ultrasound and testosterone at 6 weeks to assess recovery. Cryopreserved sperm are stored until the female partner's IVF cycle. Subsequent ICSI cycle timing is coordinated with the female partner's ovarian stimulation.
• During hormonal therapy for HH: Serial serum testosterone, LH, FSH, and semen analyses every 3 months. hCG dose adjusted to maintain testosterone in the mid-normal range (400–600 ng/dL). Add FSH if azoospermia persists at 6 months. Full spermatogenesis may require 18–24 months of treatment.
• Cabergoline monitoring: Prolactin at 1 and 3 months; MRI pituitary annually for macroprolactinoma. Semen analysis at 6 months post-initiation.
• After vasectomy reversal: Semen analysis at 4–6 weeks post-operatively to confirm patency, then every 3 months. Decline in sperm counts after initial improvement may indicate late anastomotic failure or progressive epididymal dysfunction; surgical revision or sperm retrieval with ICSI then considered.
• Psychological and psychosexual support: Male infertility imposes significant psychological burden. Integration of psychosexual counselling, peer support, and couple therapy improves quality of life and treatment adherence throughout the fertility journey.

Treatment costs vary widely by country, centre, and clinical pathway:

• Initial workup (semen analysis + hormonal panel): USD 100–500 in most countries; often subsidised under national health systems (NHS, AIIMS-India).
• Microsurgical varicocelectomy: USD 1,500–4,000 in India and Southeast Asia; USD 5,000–15,000 in the United States and Western Europe.
• microTESE (procedure alone): USD 3,000–10,000; combined with ICSI cycle and embryo transfer, total costs reach USD 8,000–22,000 depending on country.
• IVF/ICSI cycle (inclusive of drugs): USD 2,500–5,000 in India, Thailand, and Czech Republic; USD 15,000–25,000 in the US, UK, and Australia.
• Vasectomy reversal: USD 2,000–5,000 (vasovasostomy) to USD 5,000–12,000 (vasoepididymostomy) depending on complexity and surgeon expertise.
• Hormonal therapy for HH (per month): USD 200–800 depending on whether urinary or recombinant FSH is used and country of dispensing.
• Sperm cryopreservation: USD 300–800 for initial freeze + USD 300–600/year storage.
• Genetic testing (karyotype + AZF microdeletion): USD 300–900; essential before microTESE in NOA.

Medical tourism destinations such as India (NABH-accredited fertility centres), Czech Republic, Spain, and Thailand offer high-quality fertility care at 30–60% lower cost than the UK or USA without compromising outcomes at Joint Commission International (JCI)–accredited facilities.

• Donor sperm insemination (DI): Intrauterine insemination using screened donor sperm. Achieves pregnancy rates of 10–20% per cycle; most cost-effective of all assisted reproductive options. Eliminates genetic link to the male partner and requires careful counselling and legal consideration.
• Expectant management with lifestyle optimisation: In mild oligospermia with a young female partner, a 6–12 month period of timed intercourse combined with weight normalisation (BMI 20–25), smoking cessation, alcohol reduction (<14 units/week), and antioxidant supplementation is a reasonable first step before proceeding to intervention.
• Empirical antioxidant therapy: Supplementation with vitamin E (400 IU/day), vitamin C (1 g/day), coenzyme Q10 (200–600 mg/day), selenium (100 mcg/day), and zinc (66 mg/day) has mechanistic plausibility given oxidative stress in male infertility. Evidence from randomised trials is mixed; an EAU-commissioned systematic review concluded benefit is modest and these supplements should not replace established treatments.
• Empirical SERM therapy: Clomiphene citrate or tamoxifen (off-label) may raise FSH/LH in men with idiopathic oligospermia by blocking oestrogen negative feedback, but large randomised trials show only marginal semen parameter improvement and are not recommended as first-line by EAU or ASRM guidelines.
• IUI (Intrauterine Insemination): Suitable for mild male factor with total motile sperm count ≥5 million post-wash. Cumulative pregnancy rates are 35–45% over 6 IUI cycles; simpler and less expensive than IVF but with lower per-cycle success.
• Adoption: A valid family-building option that deserves discussion as part of comprehensive fertility counselling, particularly for couples with repeated treatment failures or no retrievable sperm.